HIPAA 42 CFR Part 2 – New Federal Privacy Requirements for Substance Use Disorder Treatment Information

HIPAA 42 CFR Part 2 – New Federal Privacy Requirements for Substance Use Disorder Treatment Information: Essential Compliance Insights

On February 8, 2024, the U.S. Department of Health and Human Services (HHS), in coordination with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Office for Civil Rights, issued a final regulation that significantly revises federal confidentiality standards governing SUD records.

The rule became effective following implementation requirements and organizations are now operating beyond the established compliance deadline, increasing the importance of immediate adherence and enforcement readiness.

These changes update 42 CFR Part 2 and carry out statutory directives introduced through the CARES Act, enacted on March 27, 2020. The revisions are designed to better align privacy protections for substance use treatment information with existing requirements under HIPAA and related provisions contained within the HITECH Act.

The federal statute continues to safeguard records concerning the identity, diagnosis, prognosis, and treatment of individuals receiving services connected to education, prevention, rehabilitation, research, or treatment programs addressing SUD, particularly where such programs receive direct or indirect federal support.

These confidentiality protections are intended to reduce barriers to treatment by addressing concerns regarding discrimination, stigma, and potential legal consequences that may discourage individuals from seeking care.

The final rule incorporates numerous changes originally proposed in the December 2, 2022 Notice of Proposed Rulemaking (NPRM) and reflects extensive feedback received during the public comment process.

Comments were submitted by advocacy organizations, healthcare providers, professional associations, health information exchanges, technology vendors, insurers, government entities, academic institutions, and members of the public.

After reviewing stakeholder input during the formal rulemaking process, federal agencies refined several provisions before publishing the final requirements. This webinar provides an overview of these important regulatory updates. HIPAA medical records confidentiality and confidentiality of substance use disorder; mental health records confidentiality.

The areas covered in this session include these learning objectives:

• Fundamentals of privacy and security requirements applicable to healthcare information
• Understanding why behavioral health and substance use treatment information receives additional confidentiality protections
• Overview of the federal rulemaking process and how regulations are developed and finalized
• Review of significant changes introduced by the final rule
• Analysis of current enforcement expectations and organizational obligations
• Discussion of how the OCR Civil Enforcement Program impacts covered entities, business associates, health plans, and behavioral health providers
• Examination of consent requirements, redisclosure restrictions, breach reporting obligations, patient rights, and notice requirements
• Identification of common operational risks involving EHR systems, information exchange activities, third-party vendors, workforce practices, and documentation controls
• Development of a practical compliance strategy for updating policies, procedures, consent forms, training programs, vendor management processes, and audit documentation
• Patient authorization requirements and permitted disclosures
• Breach notification obligations and enforcement considerations
• Notice requirements and available safe-harbor protections
• Best practices for obtaining, managing, and protecting sensitive patient information; and
• Practical techniques for reducing legal and regulatory exposure.

HIPAA medical records confidentiality and confidentiality of substance use disorder; mental health records confidentiality.

This webinar explores the latest federal requirements governing privacy protections for substance use treatment information and related behavioral health records.

Although the rule is relatively recent, its impact on patient rights, organizational responsibilities, and information-sharing practices has been substantial.

Attendees will gain a clear understanding of what the updated regulations require, how they affect daily operations, and the practical steps necessary to maintain compliance while protecting patient confidentiality.

• Privacy and compliance officers
• Medical records and health information management personnel
• Healthcare attorneys
• Behavioral health professionals
• Healthcare administrators; and
• Risk management personnel.